AZN vs LNTH

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

LNTH exhibits strong operational health with a Piotroski F-Score of 7/9 and robust liquidity (Current Ratio 2.70), though it lacks an Altman Z-Score for bankruptcy benchmarking. While the company is highly profitable with an ROE of 21.45% and a consistent track record of earnings beats, the stock trades at a significant premium to its Graham Number ($35.98) and Intrinsic Value ($23.87). The bullish outlook is supported by a low Forward P/E of 12.81 and a positive analyst target of $91.38, but the current price is disconnected from deterministic value metrics.